Getting your Trinity Audio player ready...

Ocugen Inc (NASDAQ:OCGN) stock has been moving higher over the past week. This morning, the company announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants and Clinical Assistant Professor at the University of Arizona, College of Medicine—Phoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal Cell and Gene Therapy Innovation Summit being held May 3, 2024 in Seattle, WA.

Intelligent Bio Solutions Inc. (NASDAQ: INBS): The company is renowned for developing the Intelligent Fingerprinting Drug Screening System, offering a novel and rapid solution for drug screening. On April 18, 2024, the company announced revenue figures for the first quarter of 2024, reporting an impressive 80% increase compared to the same period last year. For the nine-month period ending March 31, 2024, the company expects unaudited revenue of around $2.38 million, showing a substantial 193% growth from the previous year. Looking ahead, INBS anticipates continued growth, with expected cartridge and reader sales increases of 25% and 63%, respectively, from July 1, 2023, to March 31, 2024, compared to the same period the prior year. See Complete Valuation Report Here.

Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) The company is known for being the exclusive distributor of Bidi Vapor LLC products, particularly the BIDI® Stick, tailored for legal-aged nicotine users in the U.S. On March 25, Kaival Brands disclosed its financial results for the first quarter of fiscal 2024, ending on January 31, 2024. The company reported strong revenues of $3.2 million for the quarter, a notable increase from the previous year’s $2.5 million. In 2022, a significant agreement was forged with Phillip Morris Products SA (NYSE: PM) for the distribution, advancement, and development of VEEBA®, a disposable vape product, similar to BIDI® Stick. VEEBA® aims to provide convenience and simplicity for legal-aged nicotine users, offering a wide range of globally available flavors. Both companies are aligned in their mission to combat cigarette smoking.

Dyadic International Inc. (NASDAQ: DYAI) In March 2024, the company released its financial results for the fiscal year 2023, with the company reporting revenues of $2,899,000 and cash, cash equivalents, and investment-level securities valued at $7.3 million at the end of the fiscal year.  Additionally, the company successfully concluded a $6 million capital raise, sourced from relatives, trusts, and long-standing DYAI shareholders linked to Mark Emalfarm, the company’s CEO. This infusion has bolstered the company’s robust capital position. See Zacks Small-Cap Research Report, updated April 1, 2024. Finally, CEO Mark Emalfarb highlighted Dyadic’s accomplishments on “The Street Podcast,” highlighting the $75 million DuPont (NYSE: DD) deal and drawing parallels between Dyadic and Tesla, Inc.’s (NYSE: TSLA) transformative impact on the auto industry. Listen Now!

On April 24, 2024, Catheter Precision Inc. (NYSE American: VTAK), a renowned medical technology firm recognized for its VIVO™ and LockeT cardiac electrophysiology products, achieved a significant milestone by securing a purchase order for LockeT from HCA Healthcare Inc. (NYSE: HCA). This achievement holds immense importance for Catheter Precision, given HCA Healthcare’s status as a leading U.S. healthcare services provider, generating a substantial $64 billion in revenue in 2023. Operating 186 hospitals across 2,400 care sites in 20 U.S. states and the UK, HCA Healthcare’s order signifies the potential use of up to 1,000 LockeT devices annually across various medical specialties. The potential inclusion of additional prestigious academic institutions in the near to mid-term should not be unexpected.

 On April 5, 2023, Ladenburg Thalmann set a target price of $4, see buy recommendation.